Algry planning pharma charge

The new products, expected to launch in 2004 and the following year, will be developed with researchers at the University of Castilla la Mancha in Spain and manufactured by Algry Quimica.

Guillermo Rodriguez, export manager for the firm, said further details about the new ingredients would be revealed shortly. Around 90 per cent of Algry's unencapsulated choline salts are currently sold to the nutritional supplement and infant formula market but the firm is hoping to increase sales to pharma, he said.

"Our target for this year is to increase sales by between 10-15 per cent in the unencapsulated salts market," Rodriguez said. Algry also manufactures the active pharmaceutical ingredients (API) amiodarone, used in blood pressure-lowering medications.

Last year Algry reported a sales increase of 14 per cent over the 12 month-period and new marketing and distribution agreements are expected to retain this level of growth.

The Madrid-based firm opened a new facility on the south coast in 1999 allowing its products to meet high quality requirements. Its small size (around 35 people work in the plant) mean that it is flexible and can respond quickly to market demands, according to Rodriguez.